Clinical Trial Update: 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects. [Phase 1]

View source ↗

Summary

Phase 1 study evaluated the interaction between SB-649868 and the CYP3A4 enzyme after 15 days of repeated dosing in healthy male subjects, in the context of sle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• SB-649868

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sleep Initiation and Maintenance Disorders | Phase 1 | Status: COMPLETED